Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antoni Ribas

Showing results (51-60 of 467) with videos related to

Pageof 47
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
Do we need a different set of response assessment criteria for tumor immunotherapy?Antoni Ribas, Bartosz Chmielowski, John A Glaspy
Journal of Translational Medicine|November 15, 2011
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical applicationPaolo A Ascierto, Francesco M Marincola, Antoni Ribas
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 31, 2008
PET imaging of cancer immunotherapyPaul C Tumeh, Caius G Radu, Antoni Ribas
The Lancet. Oncology|May 5, 2018
Anti-PD-1 antibody treatment for melanomaAntoni Ribas, John M Kirkwood, Keith T Flaherty
Nature Reviews. Drug Discovery|December 17, 2015
Single-cell analysis tools for drug discovery and developmentJames R Heath, Antoni Ribas, Paul S Mischel
Nature Reviews. Clinical Oncology|June 1, 2018
The new era of adjuvant therapies for melanomaAlexander M M Eggermont, Caroline Robert, Antoni Ribas
Cancer Journal (Sudbury, Mass.)|January 24, 2018
Mechanisms of Resistance to PD-1 and PD-L1 BlockadeTheodore S Nowicki, Siwen Hu-Lieskovan, Antoni Ribas
Cancer Cell|June 10, 2015
Excluding T Cells: Is β-Catenin the Full Story?Siwen Hu-Lieskovan, Blanca Homet Moreno, Antoni Ribas
Cancer Discovery|October 5, 2022
When Cancer Cells Become the Enablers of an Antitumor Immune ResponseAntoni Ribas, W Nicholas Haining, Ton N M Schumacher
Cancer Research|August 2, 2011
Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibitionHubing Shi, Xiangju Kong, Antoni Ribas, et al.
Pageof 47

Showing results (51-60 of 467) with videos related to

Sort By:
Pageof 47
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
Do we need a different set of response assessment criteria for tumor immunotherapy?Antoni Ribas, Bartosz Chmielowski, John A Glaspy
Journal of Translational Medicine|November 15, 2011
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical applicationPaolo A Ascierto, Francesco M Marincola, Antoni Ribas
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 31, 2008
PET imaging of cancer immunotherapyPaul C Tumeh, Caius G Radu, Antoni Ribas
The Lancet. Oncology|May 5, 2018
Anti-PD-1 antibody treatment for melanomaAntoni Ribas, John M Kirkwood, Keith T Flaherty
Nature Reviews. Drug Discovery|December 17, 2015
Single-cell analysis tools for drug discovery and developmentJames R Heath, Antoni Ribas, Paul S Mischel
Nature Reviews. Clinical Oncology|June 1, 2018
The new era of adjuvant therapies for melanomaAlexander M M Eggermont, Caroline Robert, Antoni Ribas
Cancer Journal (Sudbury, Mass.)|January 24, 2018
Mechanisms of Resistance to PD-1 and PD-L1 BlockadeTheodore S Nowicki, Siwen Hu-Lieskovan, Antoni Ribas
Cancer Cell|June 10, 2015
Excluding T Cells: Is β-Catenin the Full Story?Siwen Hu-Lieskovan, Blanca Homet Moreno, Antoni Ribas
Cancer Discovery|October 5, 2022
When Cancer Cells Become the Enablers of an Antitumor Immune ResponseAntoni Ribas, W Nicholas Haining, Ton N M Schumacher
Cancer Research|August 2, 2011
Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibitionHubing Shi, Xiangju Kong, Antoni Ribas, et al.
Pageof 47